VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Gilead Sciences, Inc. vs Pro Medicus Limited
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisPro Medicus Limited
PME · ASX
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Pro Medicus Limited's moat claims, evidence, and risks.
View PME analysisComparison highlights
- Moat score gap: Pro Medicus Limited leads (80 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); Pro Medicus Limited has 2 segments (92.5% in Visage 7 Enterprise Imaging Platform (PACS / CloudPACS)).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; Pro Medicus Limited has 6 across 2.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Pro Medicus Limited
Visage 7 Enterprise Imaging Platform (PACS / CloudPACS)
Enterprise imaging / PACS and related modules for hospitals and integrated delivery networks (IDNs)
Primarily North America; also Europe and Australia
Hospitals, imaging centers, integrated delivery networks (IDNs)
Healthcare IT software vendor / platform provider
92.5%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
Pro Medicus Limited strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Pro Medicus Limited segments
Full profile >Visage 7 Enterprise Imaging Platform (PACS / CloudPACS)
Oligopoly
Visage RIS (Radiology Information System) and Promedicus.net
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.